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Abstract
Summary Monthly minodronate at 30 or 50 mg had similar
efficacy as 1 mg daily in terms of change in bone mineral
density (BMD) and bone turnover markers with similar
safety profiles. This new regimen provides patients with a
new option for taking minodronate.
Introduction Minodronate at a daily oral dose of 1 mg has
been proven to have antivertebral fracture efficacy. In the
present study, the efficacy and safety of oral minodronate at
monthly doses of either 30 mg or 50 mg were compared
with a daily dose of 1 mg.
Methods A total of 692 patients with involutional
osteoporosis were randomized to receive minodronate
at either 30 or 50 mg monthly or a daily dose of 1 mg.
The primary endpoint was the percent change from
baseline in lumbar spine (LS) BMD at 12 months. Total
hip BMD, bone turnover markers, serum calcium (Ca),
and parathyroid hormone (PTH) levels were also
evaluated.
Results Minodronate at monthly doses of 30 or 50 mg were
noninferior to the 1 mg daily dose in terms of change in
LS-BMD. Changes in total hip BMD were also comparable.
Although a transient decrease in serum Ca and increase in
PTH levels were observed in all three groups at slightly
different magnitudes and time courses, changes in bone
turnover markers were comparable among the different
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Conclusion Minodronate at monthly doses of 30 or 50 mg
has similar efficacy to the daily 1 mg dose in terms of BMD
and bone turnover markers with similar tolerability.
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Introduction
Minodronate is a nitrogen-containing bisphosphonate with
a potentinhibitoryeffectonboneresorption. Ina head-to-head
comparison of the effects of minodronate with alendronate in
postmenopausal osteoporosis patients, daily 1 mg minodro-
nate resulted in similar increases in lumbar spine (LS) and
total hip bone mineral density (BMD) after 12 months with
similar safety profiles [1]. A randomized placebo-controlled
trial conducted in Japan revealed that daily 1 mg minodro-
nate reduced vertebral fractures by 59% in postmenopausal
women with established osteoporosis [2]. Daily 1 mg
minodronate has been approved to treat involutional osteo-
porosis in Japan.
Most oral bisphosphonates originally developed as a
daily regimen have been shown to have equivalent
efficacy with weekly and/or monthly regimens [3–7].
Since less frequent dosing, preferred by most patients,
could result in better treatment compliance with better
outcomes [8], we conducted a study to determine if
minodronate could be administered as a monthly regimen.
The present randomized, double-blind, active-controlled
1-year study was undertaken to determine whether or not
once monthly oral minodronate at doses of 30 and 50 mg
provides similar efficacy and safety as the 1-mg daily
regimen in patients with involutional osteoporosis. The
primary efficacy analysis was the test of the noninferiority
of the mean percent change from baseline in lumbar spine
bone mineral density (LS-BMD) in the monthly minodronate
groups compared with the daily dose group after 1 year. The
safetyprofilesofthemonthly30-and50-mgregimensandthe
daily 1-mg regimen were also compared.
Materials and methods
Patient enrollment
We studied men and postmenopausal women with osteo-
porosis, aged 51 to 89 years, who had a BMD below 70%
(T-score −2.6 at the LS) of the young adult mean (YAM) or
a BMD below 80% (T-score −1.7 at the LS) of the YAM
with at least one fragility fracture, as defined by the criteria
of the Japanese Society for Bone and Mineral Research [9].
Vertebral fractures were assessed by X-ray films of the
vertebrae and were diagnosed in accordance with the criteria
of the Japanese Society for Bone and Mineral Research. Men
with a total hip BMD below 70% (T-score −2.6 at the total
hip) of the YAM were also eligible. Subjects were excluded
if they had disorders such as primary hyperparathyroidism;
Cushing's syndrome; premature menopause due to hypotha-
lamic, pituitary or gonadal insufficiency, or other causes of
secondary osteoporosis; or if there were any radiographic
findings that might affect bone densitometry assessment.
Subjects with peptic ulcer were excluded. Subjects were
excluded if they had received bisphosphonate injections,
strontium, or RANKL antibody at any time. Subjects were
also excluded if they had taken oral bisphosphonates within
the previous 1 year or for at least 30 days during the previous
2 years up until 1 year before the first dose of the study
medication. Subjects were also excluded if they had taken
glucocorticoids, calcitonin, vitamin K, active vitamin D
compounds, or hormone replacement therapy within the
previous 2 months; had serum calcium (Ca) levels above
10.6 mg/dL (2.6 mmol/L) or below 8.0 mg/dL (2.0 mmol/L);
had serum creatinine levels above 1.5 mg/dL (133 μmol/L);
or had clinically significant hepatic disorders.
This study was conducted in accordance with the
principles that have their origin in the Declaration of
Helsinki and was approved by the appropriate institutional
review boards. All subjects gave written informed consent
before undergoing any examination or study procedure, all
of which were conducted in compliance with Good Clinical
Practice. Eligibility of patients for enrollment was evaluated
by H. Hagino—Rehabilitation Division, Tottori University
Hospital, Yonago; M. Ito—Department of Radiology,
Nagasaki University School of Medicine, Nagasaki; and
T. Sone—Department of Nuclear Medicine, Kawasaki
Medical School, Okayama.
Study design
This study was a randomized, double-blind, active-
controlled, parallel-group, multicenter study conducted at
31 sites in Japan. Subjects who met all the entry criteria
were enrolled and sequentially assigned an allocation
number independent of study site. Subjects were random-
ized to take minodronate (Astellas Pharma Inc., Tokyo,
Japan) at 1 mg daily, 30 mg monthly, or 50 mg monthly for
12 months. We selected 30-mg monthly dose because it is
equivalent to 30-day daily dose of 1 mg. The dose of 50 mg
dose was selected based on the pharmacokinetics study
(data not shown) that demonstrated monthly bone exposure
comparable to daily 1 mg would require 42- to 56-mg
single monthly doses because of lower absorption with
larger single doses.
1738 Osteoporos Int (2012) 23:1737–1745Randomization was performed using a computerized
system. Subjects were instructed to take their tablet on
arising and 30 min before food with plain water. All
subjects received daily calcium (610 mg) and vitamin D
(400 IU) supplementation once a day after the evening
meal. Compliance with the study treatment was assessed
through medication diaries and by counting residual
medication supplies.
Study outcomes
The primary endpoint of the study was the test of the
noninferiority of the mean percent change from baseline in
the lumbar spine (L2–L4) BMD at 12 months of treatment
with the study medication. Secondary endpoints of the
study included mean percent change from baseline in the
total hip BMD, relative changes in bone turnover markers,
and the occurrence of new morphometric vertebral and
nonvertebral fractures.
Assessment of BMD
The lumbar spine (L2–L4) and the total hip were measured
by dual-energy X-ray absorptiometry (DXA) at baseline
and at 3, 6, 9, and 12 months to determine BMD. All 31
study centers involved in this trial were equipped with a
Hologic QDR series for BMD measurements. A central
facility (Department of Nuclear Medicine, Kawasaki Medical
School, Okayama, Japan by T. Sone) performed quality
assurance of the longitudinal adjustment. The DXA machines
wereadjustedfordifferencesandeachmachinewascalibrated
with standardized phantoms.
Assessment of bone turnover
Serum and urine samples were collected at baseline and 1,
3, 6, 9, and 12 months for measurement of bone turnover
markers, including urine type I collagen N-telopeptide
(NTX; Osteomark, Inverness Medical Japan Co., Ltd.,
Tokyo, Japan), urine deoxypyridinoline (DPD; Osteolinks
“DPD”; Quidel Corporation, San Diego, CA, USA) after
acid hydrolysis, serum bone-specific alkaline phosphatase
(BALP; AccessR OstaseR; Beckman Coulter, Inc., Brea,
CA, USA), serum osteocalcin (BGP-IRMA; Mitsubishi
Chemical Medience Corporation, Tokyo, Japan), serum Ca
(Iatrofine Ca II; Mitsubishi Chemical Medience Corpora-
tion), and serum intact parathyroid hormone (PTH;
ECLusys “PTH”; Roche Diagnostics K.K., Tokyo, Japan).
Serum 25-hydroxyvitamin D (25(OH)D 125I RIA Kit;
DiaSorin Inc., Saluggia, Italy) was also determined at
baseline. When possible, the samples for each subject were
collected around the same time of day to avoid the
influence of daily fluctuations.
Assessment of vertebral fractures
Lateral radiographs of the thoracic and lumbar spine were
taken at the screening visit to determine the presence of
prevalent fractures. Subjects were enrolled based on a
visual assessment of prevalent fractures in T4 to L4. All the
radiologic specifications and the levels of vertebra at the
thoracic and lumbar spine were standardized throughout the
study sites. The assessment of prevalent fractures was made
if the ratio of anterior or middle vertebral body height to the
posterior vertebral body height was less than 0.8 [10].
Quantitative and semiquantitative techniques [11, 12] were
used to identify incident vertebral fractures in order to
determine efficacy. Lateral radiographs of the spine were
performed at 12 months for the assessment of incident
fractures. A new vertebral fracture was diagnosed if the
anterior, posterior, or middle vertebral height had decreased
by at least 15% and by 4 mm in a vertebra that was normal
at baseline, or diagnosed semiquantitatively by grade
progression [10]. Morphological diagnosis of fractures
was made by quantitative and semiquantitative assessment
of the images using the sequence of films at the central
reading facilities of the University of Occupational and
Environmental Health, Fukuoka, Japan by T. Nakamura.
Assessment of nonvertebral fractures
All nonvertebral fractures were identified symptomatically
as clinical fractures, and only nontraumatic fractures
assessed by investigators were reported. Suspected clinical
fractures at six nonvertebral sites (humerus, radius/ulna,
subclavia, pelvis, femur, and tibia/fibula) were adjudicated
radiographically, and only radiographically confirmed
fractures were listed.
Assessment of adverse events
All subjects were questioned about treatment-emergent
adverse events (AEs) at each visit, and all adverse events
reported were analyzed regardless of the investigators'
assessments of causality. The Medical Dictionary for
Regulatory Activities (Version 13.0J) was used to categorize
reported adverse events.
Statistical analysis
The primary hypothesis of the study was that monthly
minodronate (30, 50 mg) would be comparable to daily
minodronate (1 mg) in terms of the mean percent change
from baseline in LS-BMD after 12 months of treatment.
The primary hypothesis was tested using an intention-
to-treat (ITT) analysis. The ITT population comprised all
randomized subjects. The primary analysis used a last
Osteoporos Int (2012) 23:1737–1745 1739observation carried forward approach for missing values. A
Dunnett's test was used to determine the noninferiority of
each of the monthly minodronate groups compared to the
daily minodronate group. Noninferiority was to be declared
if the lower bound of the two-sided 95% confidence
interval (95% CI) of difference did not exceed the
predefined noninferiority margin of −1.9%.
The group mean and standard deviation (SD) or standard
error (SE) were calculated for the baseline characteristics,
the percent changes from baseline in LS-BMD, total hip
BMD, and bone turnover markers and were used to assess
the significance of changes between each of the monthly
minodronate groups and the daily minodronate group. A
Dunnett's test was used to determine whether each of the
monthly minodronate groups was significantly different
from the daily minodronate group. A paired t test was used
to determine whether each of the measured values was
significantly different from the baseline. Statistical analyses
Fig. 1 Enrollment and
outcomes. A total of 1,093
patients were screened, of which
692 were randomized to take
minodronate at 30 mg monthly
(229 subjects), 50 mg monthly
(229 subjects), or 1 mg daily
(234 subjects)
Table 1 Demographics and baseline characteristics of subjects
1 mg daily (n=234) 30 mg monthly (n=229) 50 mg monthly (n=229)
Sex, n (%)
Male 2 (0.9) 7 (3.1) 5 (2.2)
Female 232 (99.1) 222 (96.9) 224 (97.8)
Age (years) 67.8 [6.870] 68.6 [7.19] 67.3 [6.53]
Body mass index (kg/m
2) 21.88 [3.101] 21.87 [2.875] 22.03 [3.248]
Menopause (years) 50.0 [4.20] 49.9 [3.81] 49.5 [4.57]
Existing vertebral fractures, n (%) 60 (25.6) 61 (26.6) 72 (31.4)
Lumbar BMD (g/cm
2) 0.6474 [0.06406] 0.6527 [0.06023] 0.6481 [0.06493]
Lumbar BMD (T-score) −3.0551 [0.53830] −3.0112 [0.50616] −3.0494 [0.54561]
Total hip BMD (g/cm
2) 0.6684 [0.07949] 0.6644 [0.08213] 0.6685 [0.08765]
Total hip BMD (T-score) −2.8791 [0.66802] −2.9129 [0.69021] −2.8784 [0.73656]
Serum 25(OH)D (ng/mL) 27.0 [5.76] 26.9 [5.94] 25.8 [5.53]
Serum BALP (U/L) 27.98 [9.165] 27.07 [8.687] 29.32 [14.321]
Serum osteocalcin (BGP, ng/mL) 8.71 [2.756] 8.61 [2.543] 8.60 [2.205]
Serum intact PTH (pg/mL) 42.2 [13.20] 43.7 [14.45] 44.1 [14.72]
Serum Ca (mg/dL) 9.31 [0.343] 9.29 [0.321] 9.33 [0.335]
Urine DPD (nmol/mmol) 6.47 [2.072] 6.54 [2.145] 6.38 [2.175]
Urine NTX (nmol BCE/mmol Cr) 46.85 [21.527] 45.67 [19.720] 46.49 [20.692]
Data are means [SD] for the indicated number of subjects in each group
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Institute). The safety analysis included all subjects who
received at least one dose of study medication in either
treatment group.
Results
Patient disposition
A total of 1,093 patients were screened; of these, 692 patients
were randomized, and 690 patients received at least one dose
of the study drug (Fig. 1). Baseline characteristics were
similar in all three treatment groups (Table 1). A similar
percentage of patients in each treatment group completed
12 months of the study (1 mg daily, 86.8%; 30 mg monthly,
91.3%; 50 mg monthly, 89.1%). The most common reason
given for withdrawal was voluntary withdrawal: 19 (61.3%)
in the 1 mg daily group; 10 (50.0%) in the 30 mg monthly
group; and 10 (40.0%) in the 50 mg monthly group.
LS and hip BMD
As shown in Fig. 2, both 30 and 50 mg monthly as well as
1 mg daily minodronate significantly increased LS-BMD
from the baseline at all time points. Noninferiority of both
monthly regimens to the daily regimen, with percent
change in LS-BMD at 12 months as the end point, was
determined. For 50 mg monthly minodronate, the estimated
treatment difference (50 mg monthly–1m gd a i l y )
was −0.294, with a 95% CI of −1.038 to 0.450, whereas
for 30-mg monthly regimen, the difference was −0.873,
with a 95% CI of −1.624 to −0.121. For both regimens, the
lower bound of the 95% CI was more than the predefined
noninferiority margin of −1.9%. At all the other time
points, both monthly regimens were not inferior to the daily
regimen by more than −1.9% (data not shown).
Total hip BMD also increased in all three regimens. The
changes were not significantly different among treatment
groups.
Bone turnover markers
Urinary NTX, DPD, serum BALP and BGP all significantly
decreased from the baseline in all treatment groups (Fig. 3).
There was no statistically significant difference in any of
the markers at any time points among treatment groups.
Serum Ca and PTH (Fig. 4)
A small but significant decrease in serum Ca level was
observed in all treatment groups at 2 weeks. At 4 weeks,
serumCa levelswerestillsignificantlylowerthanthebaseline
value in the daily and 30 mg monthly groups but not in the
50 mg monthly group. Thereafter, the serum Ca level was not
statistically different from the baseline in all the treatment
groups. At 4 weeks, serum intact PTH significantly increased
from the baseline in all the treatment groups, and the daily
group showed higher PTH than both monthly groups.
Increased PTH was maintained at 12 weeks in the daily and
50 mg monthly groups, but not in the 30 mg monthly group.
Thereafter, PTH levels returned to baseline values and were
not significantly different among groups.
Fracture
The incidences of vertebral and nonvertebral fracture were
similar among treatment groups. Morphometric vertebral
fracture occurred in six (2.6%) subjects in the daily
minodronate group, five (2.2%) in the 30 mg monthly
group, and two (0.9%) in the 50 mg monthly group.
Nonvertebral fractures were reported in six subjects (2.6%)
in the daily minodronate group (rib, femoral neck, ankle,
Fig. 2 Changes in lumbar spine and total hip bone mineral density.
Data are means±SE
Osteoporos Int (2012) 23:1737–1745 1741and three radius fractures), five subjects (2.2%) in the
30 mg monthly group [radius and ulna (one), two feet
(one), humerus (two), and foot (one)], and four subjects
(1.7%) in the 50 mg monthly group [radius and wrist (one),
rib (one), foot (one), and wrist (one)].
Safety
Overall, the drug-related AE profiles were similar in all
treatment groups (Table 2). There were no deaths in any of
the treatment groups.
Fig. 3 Changes in bone
turnover markers. Data are
means±SE
Fig. 4 Changes in serum
calcium and parathyroid
hormone levels. Data are means
±SE. a Significantly different
from baseline, p<0.05; b
significantly different from
1 mg daily group, p<0.05
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The present study demonstrated that monthly oral
administration of minodronate at a dose of 30 and
50 mg resulted in similar increases in LS and hip BMD
as daily administration at a dose of 1 mg. The changes
in bone turnover markers were also similar between
both monthly regimens and the daily regimen. Safety
profiles for the monthly regimens were similar to that of
the daily regimen. These results suggest that minodro-
nate, for which a daily dose has been shown to have
antivertebral fragility fracture (VFx) efficacy, can be
administered monthly in the same manner as risedronate
[7, 13] and ibandronate [14, 15].
In the present study, there was a transient decrease in
the serum Ca level and a transient increase in the serum
PTH level. The magnitudes and time courses of these
changes were slightly different among different regi-
mens. As shown in Fig. 3, although statistically
nonsignificant, the magnitude of the inhibition of bone
resorption markers was numerically different among
groups especially at early time points. This may well be
reflected to the differences in the changes of serum Ca and
PTH. However, the responses in terms of BMD and bone
turnover markers were not different among the three
groups. Thus, the influence of subtle differences in Ca
and PTH on bone was not clear. Similar transient changes
in Ca and PTH were previously reported with oral
alendronate [16, 17] and risedronate [18] without known
effects on bone.
The major limitation of the present study was that it
did not have the power to assess antifracture efficacy.
However, BMD change has been accepted as a valid
surrogate endpoint when evaluating a new dosage
schedule for a bisphosphonate for which a fracture
benefit has been established [3, 4, 7, 14, 19]. Thus far,
no oral bisphosphonate has demonstrated antifracture
efficacy with a weekly or monthly regimen in randomized
controlled trials. The magnitude of BMD change by
monthly minodronate in the present study was similar to
that achieved by daily minodronate in the previous
studies [1]. The changes in bone turnover markers were
also comparable [1, 2]. These data suggest that the
monthly and daily regimens of minodronate would be
equally beneficial to bone. Another limitation in this
study was that only a limited number of men were
recruited. Thus, it was impossible to analyze whether or
not minodronate would be equally effective to men as
well. However, when the data from all three regimens
were combined and analyzed using a per protocol set, the
LS-BMD change from the baseline to the end of the study
was 5.33% (95% CI 3.00–7.66) in men (n=9), which was
comparable to that in women (n=605) [6.39% (6.09–
6.70)]. The change in hip BMD was 1.10% (95%
CI −0.34 to 2.53) in men (n=8), which was smaller than
that in women (n=591) [2.94% (2.74–3.13)]. The changes
in metabolic bone markers were numerically smaller in
m e nc o m p a r e dw i t hw o m e n :c h a n g e si ns e r u mB A L P
were −37.3% (−52.5 to −22.1) in men vs −54.1% (−55.3
to −52.9) in women; serum BGP were −43.8% (−50.7 to
−36.9) in men vs −53.4% (−54.5 to 52.4) in women;
urinary NTX were −49.3% (−65.0 to −33.5) in men vs
−64.5% (−66.4 to −62.5) in women; and urinary DPD
were −19.8% (−37.3 to −2.8) in men vs −26.9% (−28.7 to
−25.0). Further studies would be needed to evaluate
whether there would be sex difference in the responses to
minodronate.
The present study demonstrated that oral minodronate
administered monthly has comparable efficacy and safety to
the daily regimen, which has been shown to have anti-VFx
efficacy. This new monthly regimen will give patients with
osteoporosis a new dosage option for minodronate, which
may lead to better medication compliance for this
bisphosphonate.
Table 2 Drug-related AEs [number of subjects (in percent)≧1%]
1 mg daily (n=234) 30 mg monthly (n=229) 50 mg monthly (n=229) Total (n=692)
Drug-related AEs 30 (12.8) 32 (14.0) 30 (13.1) 92 (13.3)
Gastrointestinal disorders 22 (9.4) 16 (7.0) 17 (7.4) 55 (7.9)
Abdominal discomfort 5 (2.1) 4 (1.7) 5 (2.2) 14 (2.0)
Abdominal pain upper 3 (1.3) 3 (1.3) 3 (1.3) 9 (1.3)
Diarrhoea 2 (0.9) 4 (1.7) 1 (0.4) 7 (1.0)
Nausea 3 (1.3) 0 (0.0) 2 (0.9) 5 (0.7)
Investigations 5 (2.1) 11 (4.8) 7 (3.1) 23 (3.3)
Alanine aminotransferase increased 0 (0.0) 3 (1.3) 0 (0.0) 3 (0.4)
Gamma-glutamyltransferase increased 0 (0.0) 5 (2.2) 0 (0.0) 5 (0.7)
Blood alkaline phosphatase decreased 5 (2.1) 1 (0.4) 3 (1.3) 9 (1.3)
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